Metronidazole for Acute Diarrhea in Dogs: Dose and Evidence

Two placebo-controlled trials have tested metronidazole for acute diarrhea in dogs, and only the Langlois trial reports its dose: metronidazole 10–15 mg/kg PO q12h for 7 days (the Shmalberg abstract does not state the dose used in that trial). But the dose is not really the question; the evidence is. In a three-arm trial of 60 dogs randomized to a probiotic combination, metronidazole, or placebo (Shmalberg et al.), metronidazole did not significantly shorten time to acceptable fecal consistency versus placebo: 4.6 ± 2.4 versus 4.8 ± 2.9 days (p = 0.17). The smaller Langlois trial of 31 dogs did find faster resolution with metronidazole (2.1 ± 1.6 versus 3.6 ± 2.1 days; P = .04), but its own authors cautioned that most dogs achieve resolution of diarrhea within several days regardless of treatment.

Study details

Langlois et al. (J Vet Intern Med 2020). Randomized, double-blinded, placebo-controlled trial: 31 dogs with acute diarrhea in which causation was not determined by routine fecal diagnostic testing were assigned to metronidazole (10–15 mg/kg PO q12h for 7 days; 14 dogs) or placebo (17 dogs). Owners maintained medication and fecal scoring logs, and fecal diagnostic tests were repeated on day 7. Mean time to resolution of diarrhea was shorter with metronidazole: 2.1 ± 1.6 days versus 3.6 ± 2.1 days (P = .04). Persistent Clostridium perfringens carriage at day 7 was lower in treated dogs (3 of 13, 23.1%, versus 11 of 14 controls, 78.6%; P = .007), though the authors note that potential relationships of C. perfringens with acute diarrhea pathogenesis were not investigated. They concluded that metronidazole can shorten duration of diarrhea and decrease fecal culture detection of C. perfringens in some dogs with acute nonspecific diarrhea, but that additional studies are needed to assess the benefits and risks of routine use because most dogs achieve resolution within several days regardless of treatment.

Shmalberg et al. (Front Vet Sci 2019). Randomized, double-blinded, placebo-controlled trial: 60 dogs without concurrent comorbidities were randomized into three treatment groups (a probiotic combination, oral metronidazole, or placebo). Time to resolution of diarrheal signs was evaluated using owner surveys and fecal scoring charts. Dogs achieved acceptable fecal consistency after 3.5 ± 2.2 days on probiotic, 4.6 ± 2.4 days on metronidazole, and 4.8 ± 2.9 days on placebo; statistically significant differences were not identified between treatment groups (p = 0.17). The authors concluded the findings failed to provide evidence for the common use of metronidazole in this cohort of dogs with acute canine diarrhea, and that a larger study population would be required to identify a statistically significant effect of probiotics.

Stewardship implication

Neither placebo-controlled trial supports reflexive empiric metronidazole for undifferentiated acute diarrhea. Shmalberg’s group stated their findings failed to provide evidence for the common use of metronidazole in this cohort, and Langlois’s group wrote that additional studies are needed to assess the benefits and risks of routine use “because most dogs achieve resolution of diarrhea within several days regardless of treatment.” The risk side is not hypothetical: a retrospective series of 26 dogs with metronidazole-induced neurotoxicity identified from four referral hospitals (2004–2017) reported a median treatment dosage of 21 mg/kg BID (range, 13–56 mg/kg every 12 h), median treatment duration of 35 days (range, 5–180 days), and median resolution of signs 3 days after discontinuation (range, 1–26 days); its authors found neurotoxicity at much lower doses than previously reported and advise caution at doses above 40 mg/kg every 24 h, regardless of treatment duration. The Langlois regimen (10–15 mg/kg q12h) totals 20–30 mg/kg/day, below that caution threshold.

When metronidazole IS indicated

Metronidazole is an antibacterial, antiprotozoal, and anthelmintic medication commonly used in veterinary medicine, and it remains a defensible choice when therapy is directed at a confirmed or strongly suspected etiology (Giardia infection or a susceptible anaerobic bacterial infection, for example). The Merck Veterinary Manual cites metronidazole as effective in the treatment of giardiasis and active against obligate anaerobic bacteria. The trials above studied a different question: dogs with acute diarrhea in which causation was not established by routine fecal diagnostics. Thin evidence for empiric coverage of nonspecific diarrhea is not evidence against targeted treatment of a diagnosed enteropathogen.

Clinical context and limitations

• Both trials were small (n = 31 and n = 60); modest true effects cannot be excluded, and the Shmalberg abstract explicitly notes a larger study population would be required to reach statistical significance for the probiotic arm. The same sample-size caution applies to interpreting its null metronidazole result.
• Shmalberg enrolled dogs without concurrent comorbidities; Langlois enrolled dogs without an established cause on routine fecal testing. Neither supports extrapolation to acute hemorrhagic diarrhea syndrome, systemically ill or hospitalized dogs, or dogs with confirmed enteropathogen infection.
• The Langlois trial was funded by Zomedica, Inc., and its first author serves on a Zomedica scientific advisory board per the PubMed record’s conflict-of-interest statement (worth weighing when reading its positive efficacy signal).
• The neurotoxicity series is retrospective and referral-hospital based; its dose figures describe affected cases, not population incidence.

Ask Vetinuity

For follow-up questions about the Langlois dosing regimen, the neurotoxicity case series, or antimicrobial stewardship in acute diarrhea, ask the Vetinuity clinical assistant.